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Background: Existence of coronary endothelial dysfunction has been demonstrated in pa-
tients with cardiac syndrome X (CSX). In addition, Helicobacter pylorus (H. pylori) has been
associated with CSX. We aimed to assess the possible association of endothelial
dysfunction and cytotoxin-associated gene A-positive H. pylori (CagAþ) infection in CSX
patients.
Methods: Fifty-six patients with CSX (23 male/33 female; age: 51.25 ± 8.86 years) who were
anti-H. pylori IgG-positive [H. pylori(þ)] and 24 CSX patients (7 male/17 female; age:
52.79 ± 9.88 years) who were H. pylori() were included. Also, anti-H. pylori IgG-positive
patients were determined by the presence of IgG antibody to CagA. Levels of endothelin-1
(ET-1), E-selectin and intercellular adhesion molecule-1 (ICAM-1) were measured.
Results: Endothelial dysfunction biomarkers were higher in H. pylori(þ) than in H. pylori()
patients (ET-1: 54.60 ± 25.39 vs. 42.59 ± 18.37 pg/ml, p ¼ 0.04; E-selectin: 42.68 ± 14.26 vs.
31.72 ± 8.26 ng/ml, p ¼ 0.001; ICAM-1: 339.68 ± 135.8 vs. 266.51 ± 125.1 ng/ml, p ¼ 0.02).
Among H. pylori(þ) subjects, 28 cases were CagA(þ) and 28 cases were CagA(). There were
significant differences in measured levels of E-selectin between CagA(þ) and CagA()
groups (48.00 ± 16.37 vs. 37.37 ± 9.37 ng/ml, p ¼ 0.004). For ET-1 and ICAM-1 levels, the
difference between CagA(þ) and CagA() was insignificant (p ¼ 0.174 and p ¼ 0.07,
respectively).
Conclusion: High levels of endothelial dysfunction biomarkers are found in CSX patients
with anti-CagA(þ). These findings suggest the infection with CagA(þ) H. pylori strain may
play a role as a risk factor in development of CSX through provocation of endothelial
dysfunction. Therefore, a long term follow up to investigate the outcomes of these patients
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Scientific background on the subject
Cardiac syndrome X (CSX) describes patients with
angina-like chest pain, a positive exercise stress test
result, and angiographically normal epicardial coronary
arteries. Endothelial dysfunction is among the most
commonly suggested pathogenic mechanisms respon-
sible for CSX. Previous studies have revealed an associ-
ation between Helicobacter pylori (H. pylori) infection with
vascular discomforts. Specifically, strains bearing the
cytotoxin-associated gene A [CagA(+)] exacerbate a
heightened inflammatory response in vivo. In this study
we would like to see whether infection with CagA(+)
bearing strain of H. pylori is associated with higher
endothelial dysfunction.
What this study adds to the field
Study results show the infection with CagA(+) H. pylori
weather play a role as a risk factor in development of
CSX through provocation of endothelial dysfunction.Cardiac syndrome X (CSX) describes patients with angina-
like chest pain, a positive exercise stress test result, and an-
giographically normal epicardial coronary arteries [1]. More
than 40 years after the first description of the disease, the
debate continues to the CSX mechanisms. Inflammation and
microvascular dysfunction are among the most commonly
suggested pathogenic mechanisms responsible for CSX [1e3].
The endothelial function has been studied mainly by invasive
methods and by measuring humoral factors [4]. Increased
levels of plasma adhesion molecules like soluble intercellular
adhesion molecule-1 (sICAM-1) and soluble E-selectin (sE-
selectin) have been considered as markers of endothelial
injury [4,5]. For example, Senen et al. [6] found increased
plasma concentrations of ICAM-1 and sE-selectin in CSX pa-
tients. Moreover, it is known that damaged or activated
endothelial cells can secrete vasoconstrictor factors such as
endothelin-1(ET-1). Kaski et al. [7] suggested the association
between high plasma concentrations of ET-1 and genesis of
chest pain in patients with CSX.
On the other hand, previous studies have revealed an as-
sociation between Helicobacter pylori (H. pylori) infection with
vascular discomforts [8,9]. H. pylori is a microaerophilic spiral
shaped gram negative bacterium that colonizes the gastric
lumen of humans and other primates [10]. It may cause extra-
intestinal expressions such as functional ischemic heart dis-
ease [11,12] and it has recently been associated with CSX
[9,13]. There is genetic diversity between H. pylori strains that
affects virulence [14]. Specifically, strains bearing the
cytotoxin-associated gene A [CagA(þ)] exacerbate a height-
ened inflammatory response in vivo [15]. The virulent CagA(þ)
may induce a more consistent release of cytokines withvasoactive properties, which might be the basis of systemic
extradigestive effects that led to cardiac microvascular
dysfunction [8]. We aimed to evaluate the possible association
of chronic CagA(þ) infection and endothelial dysfunction in
CSX patients.Methods
Patient characteristics
The present study included 80 patients (30 male/50 female;
mean age: 51.71 ± 9.2 years) who had been diagnosed as CSX.
The entry criteria of CSX were recurrent typical angina chest
pain at rest and on effort, a normal 12-lead electrocardiogram
at rest, positive exercise ECG stress test response and normal
coronary angiogram. Patients with evidence of myocardial
infarction, valvular heart disease, left and right ventricular
dysfunction, concomitant acute and chronic disease were
excluded from the study. Also, patients with diabetesmellitus
were not included, as endothelial dysfunction markers in-
crease in diabetes mellitus. Non-cardiac causes of chest pain
such as gastrointestinal and musculoskeletal disorders were
also investigated and ruled out as appropriate. All subjects
gave their informed consent prior to their inclusion in the
study. The study protocol approved by the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in the guide-
lines of theMedical Ethics Committee, Ministry of Health, Iran
by our university of Medical Research Ethics committee
(approved number: 481). A questionnaire was administrated
to obtain general information regarding age, sex, body mass
index (BMI), systolic and diastolic blood pressures.Measurement of parameters
EDTA-anticoagulated peripheral blood sample was taken from
each subject in resting on the same day that clinical data were
recorded and the plasmawas obtained after a centrifugation of
3000 rpm for 10 min. Collected plasma for determination of
biomarkers of endothelial function (sICAM-1 and sE-selectin
and ET-1) were stored at 80 C before laboratory testing.
Specific anti-H. pylori immunoglobulin-G (IgG) positivity
was determined with a commercial enzyme-linked immuno-
sorbent assay (ELISA) kit (H. pylori-IgG and CagAeIgG, Enzyme
Immunoassay; Dia pro, Italy) according to the manufacturer's
instructions.
Also, plasma positivity to the antigen CagA was assessed
by ELISA (Dia.Pro, Milan, Italy; sensitivity and specificity >98%)
in anti-H. pylori positive (anti-H. pyloriþ) samples.
Endothelial function markers were measured using
commercially available kits for measurement of ICAM-1 and
sE-selectin levels (Platinum ELISA, Bender Med Systems,
Austria). In addition, plasma levels of ET-1 were measured
using immunosorbent assay method (Human ET-1, USCN
LIFE, USA).
Laboratory glucose and lipid profile results used for com-
parison of baseline characteristics. These routine tests are
performed for any patient admitted to hospital.
Table 1 e Demographic and baseline clinical characteristics of patients with cardiac syndrome X.
Variable H. pylori() (n ¼ 24) H. pylori(þ) (n ¼ 56) p-value H. pylori status p-value
CagA() (n ¼ 28) CagA(þ) (n ¼ 28)
Age (years) 52.79 ± 9.88 51.25 ± 8.86 p ¼ 0.493 52.18 ± 11.11 50.32 ± 5.91 p ¼ 0.438
Sex (M/F) 7/17 23/33 p ¼ 0.450 9/19 14/14 p ¼ 0.139
(BMI) (Kg/m2) 26.48 ± 2.51 26.56 ± 5.90 p ¼ 0.949 27.82 ± 6.04 25.31 ± 5.60 p ¼ 0.113
Smokers, n(%) 2 (8.3%) 11 (19.6%) p ¼ 0.324 5 (17.9%) 6 (21.4%) p ¼ 0.500
SBP (mmHg) 113.75 ± 11.35 115.18 ± 10.44 p ¼ 0.586 117.50 ± 13.23 112.86 ± 6.00 p ¼ 0.197
DBP (mmHg) 71.04 ± 4.42 74.20 ± 8.67 p ¼ 0.096 72.86 ± 10.50 75.54 ± 6.29 p ¼ 0.252
FBS (mg/dl) 91.24 ± 6.83 94.52 ± 5.72 p ¼ 0.454 92.24 ± 7.33 96.01 ± 8.02 p ¼ 0.383
TC (mg/dl) 163.50 ± 11.43 159.33 ± 14.02 p ¼ 0.332 158 ± 13.56 164.44 ± 11.66 p ¼ 0.298
LDL (mg/dl) 86.4 ± 8.9 92.06 ± 83 p ¼ 0.139 94.1 ± 6.22 89.62 ± 5.7 p ¼ 0.212
HDL (mg/dl) 44.52 ± 10.85 46.22 ± 10.93 p ¼ 0.789 46.5 ± 11.8 39.12 ± 12.86 p ¼ 0.286
TG (mg/dl) 148.14 ± 22.8 154.30 ± 18.54 p ¼ 0.632 158.32 ± 20.22 144.30 ± 24.45 p ¼ 0.294
All values are means ± SD. Abbreviations: H. pylori: Helicobacter pylori; CagA: cytotoxin-associated gene A; BMI: body mass index; SBP: systolic
blood pressure; DBP: diastolic blood pressure; FBS: fasting blood sugar; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density
lipoprotein; TG: triglyceride.
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Data analysis was conducted using Statistical Package of the
Social Sciences (IBM SPSS Statistics 19) software.
Chi square and independent sample T tests were carried
out for statistic analysis. Age, systolic blood pressure, diastolic
blood pressure, glucose, lipid profile and body mass index
(BMI) were shown as mean ± standard deviation (SD). One-
Way ANOVA with Tukey HSD test used to compare amount
of endothelial function markers among three groups. Statis-
tical significance was defined as a p-value <0.05.Results
All individuals diagnosed as CSX and there were no significant
differences in the medication status. Baseline characteristics
are not different among the groups in respect to age, sex, BMI,
smoking, systolic and diastolic blood pressure, glucose, lipids
and medications [p > 0.05, Table 1].
At first, we divided CSX patients into two groups according
to the presence (23 male/33 female, mean age: 51.25 ± 8.86) or
absence (7 male/17 female, mean age: 52.79 ± 9.88) of anti-H.
pylori IgG antibody (H. pylori(þ) and H. pylori(), respectively).
The measured plasma concentrations of ET-1 were signifi-
cantly greater in H. pylori(þ) than in H. pylori() patients
(54.60 ± 25.39 vs. 42.59 ± 18.37 pg/ml, p ¼ 0.040). Also the
plasma E-selectin levels were higher in H. pylori(þ) than in H.
pylori() patients (42.68 ± 14.26 vs. 31.72 ± 8.26 ng/ml,
p ¼ 0.001). These patterns also were seen in plasma levels of
ICAM-1. The levels of ICAM-1 concentration in H. pylori(þ)
were higher than H. pylori() patients (339.68 ± 135.8 vs.
266.51 ± 125.1 ng/ml, p ¼ 0.02).
In the second step, the H. pylori(þ) group divided into two
sub-groups according to presence (14 male/14 female, mean
age: 50.32 ± 5.91 years) or absence (9 male/19 female, mean
age: 52.18 ± 11.11 years) of anti-CagA IgG antibody (CagA(þ)
and CagA(), respectively). Differences in plasma levels of ET-
1 in CagA(þ) and CagA() groups was insignificant
(60.21 ± 25.12 vs. 49.00 ± 24.83 pg/ml, p ¼ 0.174). Furthermore,levels of plasma E-selectin levels in CagA(þ) patients were
much greater than CagA() patients (48.00 ± 16.37 vs.
37.37 ± 9.37 ng/ml, p¼ 0.004; [Table 2]). Greater concentrations
of ICAM-1 are also seen in CagA(þ) patients than CagA()
patients (388.34 ± 149.38 vs. 308.87 ± 120.11 ng/ml, p ¼ 0.070).
According to multiple comparison procedures, the
increased levels of plasma ET-1 concentrations in CagA(þ)
group than H. pylori(), were significant (p ¼ 0.021). The mean
of plasma E-selectin in CagA(þ) group were higher than H.
pylori() group (p < 0.0001). This pattern also seen for ICAM-1;
the mean in CagA(þ) group was greater than in H. pylori()
group (p ¼ 0.004), [Fig. 1].Discussion
CSX is a heterogeneous condition that encompasses several
possible causal mechanisms. Cardiac and non-cardiac mech-
anisms have been proposed, among which endothelial
dysfunction of the coronary microcirculation features promi-
nently [3]. Current research suggests that coronary endothelial
dysfunction and subsequent microvascular ischemia is the
likely pathophysiologic mechanism for patients with CSX,
which results in their angina-like chest pain [1]. H. pylori
recently has been associated with CSX. In a previous case-
control study we showed the high frequency of H. pylori in
CSX [16]. Eskandarian et al. [17], showed that 95% of CSX pa-
tients were H. pylori(þ), while only 47.5% of healthy control
group were infected. Recent findings suggest that there are
relations between chronic infection of H. pylori and endothelial
dysfunction. Innocenti et al. [18] showed that H. pylori induced
activation of human endothelial cells. Also, Oshima et al. [19]
studied the association of H. pylori infection with systemic
inflammation and endothelial dysfunction in healthy male
subjects. They reported that chronic infection of H. pylori
involved in the development of the atherosclerosis via endo-
thelial dysfunction. These studies are consistent with our
findings which all three endothelial dysfunction markers were
significantly higher in H. pylori(þ) than H. pylori() groups. We
speculated that H. pylori may also cause endothelial
Table 2 e Multiple comparisons.
Dependent variable (I) HP_CagA (J) HP_CagA Mean difference (IJ) Std. error Sig. 95% Confidence interval
Lower bound Upper bound
Endothelin Tukey HSD HPpCAGp HPpCAGn 11.20567 6.20094 0.174 3.6137 26.0251
HPnCAGn 17.61515a 6.45415 0.021 2.1906 33.0397
HPpCAGn HPpCAGp 11.20567 6.20094 0.174 26.0251 3.6137
HPnCAGn 6.40948 6.45415 0.583 9.0150 21.8340
HPnCAGn HPpCAGp 17.61515a 6.45415 0.021 33.0397 2.1906
HPpCAGn 6.40948 6.45415 0.583 21.8340 9.0150
LSD HPpCAGp HPpCAGn 11.20567 6.20094 0.075 1.1420 23.5533
HPnCAGn 17.61515a 6.45415 0.008 4.7633 30.4670
HPpCAGn HPpCAGp 11.20567 6.20094 0.075 23.5533 1.1420
HPnCAGn 6.40948 6.45415 0.324 6.4424 19.2613
HPnCAGn HPpCAGp 17.61515a 6.45415 0.008 30.4670 4.7633
HPpCAGn 6.40948 6.45415 0.324 19.2613 6.4424
sEselectin Tukey HSD HPpCAGp HPpCAGn 10.62429a 3.21998 0.004 2.9290 18.3196
HPnCAGn 16.27393a 3.35146 0.000 8.2644 24.2835
HPpCAGn HPpCAGp 10.62429a 3.21998 0.004 18.3196 2.9290
HPnCAGn 5.64964 3.35146 0.217 2.3599 13.6592
HPnCAGn HPpCAGp 16.27393a 3.35146 0.000 24.2835 8.2644
HPpCAGn 5.64964 3.35146 0.217 13.6592 2.3599
LSD HPpCAGp HPpCAGn 10.62429a 3.21998 0.001 4.2125 17.0361
HPnCAGn 16.27393a 3.35146 0.000 9.6003 22.9475
HPpCAGn HPpCAGp 10.62429a 3.21998 0.001 17.0361 4.2125
HPnCAGn 5.64964 3.35146 0.096 1.0240 12.3233
HPnCAGn HPpCAGp 16.27393a 3.35146 0.000 22.9475 9.6003
HPpCAGn 5.64964 3.35146 0.096 12.3233 1.0240
ICAM1 Tukey HSD HPpCAGp HPpCAGn 79.47500 35.41326 0.070 5.1578 164.1078
HPnCAGn 121.83464a 36.85929 0.004 33.7460 209.9233
HPpCAGn HPpCAGp 79.47500 35.41326 0.070 164.1078 5.1578
HPnCAGn 42.35964 36.85929 0.487 45.7290 130.4483
HPnCAGn HPpCAGp 121.83464a 36.85929 0.004 209.9233 33.7460
HPpCAGn 42.35964 36.85929 0.487 130.4483 45.7290
LSD HPpCAGp HPpCAGn 79.47500a 35.41326 0.028 8.9582 149.9918
HPnCAGn 121.83464a 36.85929 0.001 48.4384 195.2309
HPpCAGn HPpCAGp 79.47500a 35.41326 0.028 149.9918 8.9582
HPnCAGn 42.35964 36.85929 0.254 31.0366 115.7559
HPnCAGn HPpCAGp 121.83464a 36.85929 0.001 195.2309 48.4384
HPpCAGn 42.35964 36.85929 0.254 115.7559 31.0366
a The mean difference is significant at the 0.05 level.
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vascular endothelial cells via inflammation in CSX [20].
On the other hand, a number of virulence factors of H.
pylori are associatedwith disease outcome, including the CagA
[21]. CagA is a 128-kDa H. pylori antigen, associated with
enhanced virulence and cytotoxin production [22]. Recently
researchers have revealed an association between CagA(þ)
strains and rigorous forms of gastrointestinal diseases
including peptic ulcer and gastric cancer [15,23,24]. CagA
recently has been associated with CSX [17,25].
Although prevalence of CagA has been studied widely in
gastrointestinal diseases, but no previous study has investi-
gated the possible association of these more virulent H. pylori
strains in CSX patients with involvement of endothelial
dysfunction. In this study, we compared the levels of three
plasma endothelial dysfunction markers, ICAM-1, sE-selectin
and ET-1 among three CSX patient groups including CagA(þ)
H. pylori, CagA() H. pylori and H. pylori() that were statisti-
cally similar for age, sex, BMI, blood pressure, lipids, glucose,
smoking and medications. We showed that the CSX patientswith CagA bearing strain of H. pylori chronic infection have
significantly higher levels of plasma soluble endothelial
dysfunction markers when compared to CagA(), or even H.
pylori() groups. Therefore, finding the “High” levels of plasma
soluble adhesion molecules; ICAM-1 and sE-selectin in
CagA(þ) group than CagA() and H. pylori() groups in the
present study suggests that CagA(þ) strain of this bacterium
may be more associated with endothelial activation. Also, in
this study, themeasured levels of ET-1 in CagA(þ) were higher
than H. pylori() group and tended to be greater than CagA()
patients. This also may indicate that the main association
between H. pylori infection and endothelial dysfunction is due
to CagA(þ) H. pylori infection.
Recent researches suggest a role of inflammation in the
pathogenesis of endothelial dysfunction and correlation of
CRP-concentration (C-Reactive Protein, a sensitive marker of
inflammation) with severity of symptoms in patients with
CSX [26,27]. Chronic inflammation leads to an increase in the
generation of pro-inflammatory cytokines, cell adhesion
molecules and growth factors that can elicit inflammatory
Fig. 1 e Plasma levels of measured endothelial dysfunction
markers in patients with CSX. The means of plasma levels of
ET-1, E-selectin and ICAM-1 compared among three groups.
The groups consisted of CagA(þ) [CagA IgG(þ)H. pylori IgG(þ)],
CagA() [CagA IgG() H. pylori IgG(þ)] andH. pylori() [H. pylori
IgG()]. Abbreviations used: H. pylori: Helicobacter pylori; CagA:
cytotoxin-associated gene A; ICAM-1: intercellular adhesion
molecule-1.
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endothelial dysfunction [25]. In a previous case-control study,
we investigated the association of inflammation and CagA(þ)
strains of H. pylori in CSX using inflammationmarkers such as
Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a).We found that the CagA positive strain ofH. pylori can not only
be a trigger, and may also have a role via chronic inflamma-
tion in the pathogenesis of CSX [28]. Previous studies showed
the contribution of endothelium to the inflammatory
response with regard to production of cytokine and chemo-
kine after infection with pathogenic bacteria like H. pylori [29].
During inflammatory responses, the transcription factor nu-
clear factor kappa B (NF-kB) plays a key role in the regulation
of participating genes [30]. The expression of ICAM-1 and E-
Selectin is under NF-kB control in endothelial cells [31] and
NF-kB activation has been shown during infection with H.
pylori [32]. Giving these information together, it is possible that
CagA(þ) may induce upregulation of special expression fac-
tors that led to higher levels of endothelial dysfunction
markers in plasma of CagA(þ) group in this study.
In this study, we had some limitations. Our criteria for
being diagnosed as infection were IgG positivity to H. pylori.
Because positivity of IgG to H. pylori can provide evidence of
chronic infection even following eradication of H. pylori
[33,34], it is possible some of our patients not to have current
active infection and probably they have been infected in the
past. Therefore, it should be considered that infection to H.
pylori in this research means patients who their plasma is
currently positive for anti-H. pylori IgG antibody. Themean age
of the CSX patients in this study were 51 which nearly consist
of 2/3 female individuals. As CAD prevalence in middle age is
low, resulting in high pseudopositive exercise stress test re-
sults and this was another limitation in our study.
After all, it should be added that well designed clinical trial
studies might to be needed to further confirm these results.
Although all patients in this study were CSX patients, studies
with adjoining normal controls by regarding H. pylori and
CagA status and by using non-humoral endothelial dysfunc-
tion evaluation methods like FMD is proposed. In addition, a
study with H. pylori eradication and following up the angina
symptoms and endothelial function quality propose to future
investigation. Currently we can not prove the eradication ofH.
pylori infection can either improve angina symptom or pro-
gression of atherosclerosis.Conclusion
The conclusion drawn from the results is that high levels of
markers of endothelial dysfunction are related with CagA(þ)
H. pylori infection in patients with CSX, given contributors to
endothelial dysfunction including age, sex, obesity, blood
pressure, lipid, glucose, smoking and medications are statis-
tically controlled. Consequently, the possible role of CagA(þ)
infection in the pathogenesis of CSX with involvement of
endothelial dysfunction is suggested. This study revealed that
patients with chronic CagA(þ) H. pylori infection have high
degree of endothelial dysfunction.Conflicts of interest
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